A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
ConditionAtopic Dermatitis (AD)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBluefin Biomedicine, Inc.
About this trial
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Eligibility criteria
Qualifiers
Are adults (18-75) with a diagnosis of atopic dermatitis for at least one year.
Have moderate to severe disease not adequately controlled by topical treatments.
Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.
Disqualifiers
Have certain infections or other immune conditions.
Recently used medications that could interfere with the study.
Are pregnant or breastfeeding.
Trial design
Treatments tested in this trial
- BFB759
- Placebo
Treatment groups
225 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov